Healthcare Economist September 20, 2021
That is the question that a recent JAMA study–Mulcahy et al. (2021)–aim to answer. The authors use IQVIA MIDAS data to estimate sales price and volume in the US. These can can be used to estimate drug wholesale acquisition cost (WAC), but they ignore rebates. To account for rebates in the US they use SSR Health information Then international prices are identified based on the IQVIA MIDAS data across 6 markets (Australia, Canada, France, Germany, Japan, and the U.K). The authors then calculate US wholesale prices, US net prices and what US prices would be if drugs were reference priced to these 6 markets. Based on this approach, they find that:
International reference pricing would have lowered 2020 US...
Today's Sponsors
Today's Sponsor